左心室变形和组织特征在高压心肌病患者的高压心肌病:一个CMR研究研究
Jian Liu1, Zhengkai Zhao1, Qiuyi Cai1
1Department of Radiology, The Third People's Hospital of Chengdu, Chengdu, 610000, China.
BMC medical imaging
|December 8, 2025
概括
患有缩性心肌病和心力衰竭的患者,其喷射分数被保存,显示左心室应变和纤维化受损. 心脏磁共振成像有助于识别这些变化,并预测心力衰竭状态.
科学领域:
- 心脏病学 心脏病学
- 心血管成像 - 心血管成像
- 生物医学工程 生物医学工程
背景情况:
- 超性心肌病 (HCM) 可以导致心力衰竭与保存的喷射分数 (HFpEF).
- 评估左心室 (LV) 功能和心肌组织特征对于管理HCM患者的HFpEF至关重要.
研究的目的:
- 用心磁共振 (CMR) 来评估 LV 变形和组织特征,用于患有或没有 HFpEF 的 HCM 患者.
- 检查CMR参数与心力衰竭状态之间的关联.
- 探索CMR参数与H2FPEF评分之间的相关性.
主要方法:
- 对105名接受3.0-TCMR的HCM患者进行了回顾性分析.
- 根据2019年ESC HFA-PEFF算法对HFpEF (n=46) 和非HF (n=59) 组进行分类.
- 使用CMR特征追踪推导LV菌株 (GRS,GCS,GLS) 和菌株速率.
- 心肌组织的表征包括原生T1/T2映射,细胞外体积分数 (ECV) 和晚期加多增强 (LGE).
主要成果:
- 与非HF患者相比,患有HFpEF的HCM患者表现出较低的LV缩和早期腹缩应变率 (sGRSr,sGCSr,sGLSr,eGLSr).
- 在HFpEF组显示较高的LGE的流行/程度和高原T1和ECV值.
- 较低的LV-eGLSr和较高的细分ECV是HFpEF的独立预测因素,除了心房动和饮酒.
- H2FPEF得分与原生T1,ECV和T2值有显著的相关性.
结论:
- 患有HFpEF的HCM患者表现出心缩和心缩功能障碍,心肌纤维化增加.
- 从CMR衍生的菌株 (LV-eGLSr) 和组织特征 (ECV) 是HCM中HFpEF的独立预测因子.
- 包括菌株和组织特征在内的CMR参数补充了H2FPEF评分,用于早期检测和在HCM中对HFpEF风险分层.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
374
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
374
Heart Failure II: Pathophysiology
685
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
685
Cardiomyopathy IV: Restrictive Cardiomyopathy
431
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
431
Mitral Stenosis II: Clinical features and Diagnostic Tests
196
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
196
Cardiomyopathy II: Dilated Cardiomyopathy
447
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
447


